Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-ĸB Activation

Kun-Ching Lee,Wei-Ting Chen,Yu-Chang Liu,Song-Shei Lin,Fei-Ting Hsu,KUN-CHING LEE,WEI-TING CHEN,YU-CHANG LIU,SONG-SHEI LIN,FEI-TING HSU
DOI: https://doi.org/10.21873/invivo.11351
2018-01-01
In Vivo
Abstract:AIM: The aim of the present study was to confirm therapeutic efficacy and find probable mechanism of action of amentoflavone in hepatocellular carcinoma (HCC) in vivo.MATERIALS AND METHODS: Luciferase reporter vector pGL4.50_transfected SK-Hep1 (SK-Hep1/luc2) tumor-bearing mice were treated with vehicle or amentoflavone (100 mg/kg/day by gavage) for 14 days. Tumor growth, amentoflavone toxicity, and extracellular signal-regulated kinase (ERK)/nuclear factor-kappaB (NF-ĸB) signaling in tumor progression were evaluated with digital caliper, bioluminescence imaging, computed tomography, body weight, pathological examination of liver, and immunohistochemistry staining.RESULTS: Amentoflavone significantly inhibited tumor growth, ERK/NF-ĸB activation, and expression of tumor progression-associated proteins as compared to vehicle-treated group. In addition, body weight and liver morphology of mice were not influenced by amentoflavone treatment.CONCLUSION: These results suggest that amentoflavone inhibits HCC progression through suppression of ERK/NF-ĸB signaling.
medicine, research & experimental
What problem does this paper attempt to address?